Agenus Consensus Price Target Increased by 35.04% to $26.86
The average one-year price target for Agenus (NASDAQCM:AGEN) (DB:AJ8) has been revised to $26.86 / share, an increase of 35.04% from the prior mean of $19.89 dated September 11, 2026. These figures represent aggregate analyst targets compiled from multiple sources and do not constitute a recommendation orinvestment adviceby Fintel.
Individual analyst targets range from a low of $14.14 to a high of $42.00 / share, widening the target range from its prior width of $12.11 (prior low $14.14 and high $26.25) to a current width of $27.86, a target range width change of +130.06%. As of September 29, 2026, the current median target is $25.50, representing an absolute median change of $5.61 from the prior median of $19.89. The current mean-median gap is $1.36. The average price target represents an increase of 222.45% from the latest reported closing price of $8.33 / share on October 1, 2026.
Historically, the mean target was recorded at $19.89 on September 16, 2026, and August 28, 2026, following a mean of $22.44 on August 4, 2026. On October 2, 2026, the mean target was $26.86. The observed twelve-month high mean target of $26.86 was recorded on October 2, 2026, while the observed twelve-month low mean target of $12.58 was recorded on March 28, 2026. This current target represents a +69.89% change since the 90-day baseline date of July 2, 2026.
Recent analyst actions include Rodman & Renshaw initiating coverage with a Buy grade on September 28, 2026, and Chardan Capital initiating coverage with a Buy grade on September 18, 2026.
Agenus is a biotechnology company based in Lexington, Massachusetts, focused on immunology and the development of therapies that engage the body's immune system to fight cancer and infections.
Among its peers, target revisions and implied changes showed mixed directions.
| Company | Target revision | Implied change |
|---|---|---|
| TuHURA Biosciences | 0.00% | +314.18% |
| PDS Biotechnology | -13.79% | +501.90% |
| Xencor | +4.19% | +30.28% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.